跳至主要内容
临床试验/DRKS00026205
DRKS00026205招募中未知

Predictive relevance of genetic polymorphisms in the glycogen-synthase-kinase-3beta (GSK3B) mediated intracellular signal transduction for the efficacy of lithium augmentation of antidepressants in the treatment-resistant major depression - ALIA

Charité - Universitätsmedzin Berlin0 个研究点目标入组 500 人开始时间: 2021年9月14日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • unipolar major depression
  • -indication for antidepressant pharmacotherapy
  • -HAMD-17 = 12
  • -Inadequate response to antidepressant monotherapy and indication for lithium augmentation.
  • -Minimum age: 18 years
  • -physician-confirmed capacity to consent
  • -written informed consent
  • -No participation in an AMG study (1 month prior) and during study participation.

排除标准

  • -psychotic symptoms, current
  • -Contraindication to lithium therapy (e.g. severe renal insufficiency, pathological TSH or relevant ECG changes) - for a list of contraindications, see the technical information in the appendix.
  • -laboratory values and/or ECG findings that speak against taking lithium
  • -depressive syndrome due to a non-psychiatric or in the context of a further axis I diagnosis
  • -diagnosis of dementia or organic brain disease
  • -Diagnosis of substance dependence and use of the substance in the last 6 months (except caffeine and nicotine)
  • -Diagnosis of an antisocial personality disorder

研究者

发起方
Charité - Universitätsmedzin Berlin

相似试验